SS Innovations International Inc. (NASDAQ: SSII) has helped establish Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, using the company's SSi Mantra 3.0 surgical robotic system. The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The development was highlighted in a recent company video describing the program's early activity.
According to the video, Kings Hospital has completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption of the technology. This launch marks a significant step for Sri Lanka's healthcare sector, which has historically relied on traditional open-heart surgery. Robotic-assisted cardiac surgery offers the potential for smaller incisions, reduced pain, and faster patient recovery times, though it requires specialized training and equipment.
The milestone comes as SS Innovations reports growing momentum in its business. At the end of the second quarter, the company had 224 cumulative SSi Mantra installations across 12 countries. Second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, indicating rising utilization of the company's installed base. These figures suggest that hospitals are not only adopting the system but also using it more frequently, which could drive recurring revenue and strengthen SS Innovations' market position.
For investors, the expansion into new geographies like Sri Lanka signals the company's ability to penetrate diverse markets and compete with larger players in the surgical robotics industry. The next major corporate milestone is regulatory expansion, with SS Innovations pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Success in these regulatory efforts could open doors to the world's largest healthcare markets, significantly expanding the company's addressable market and revenue potential.
The news is also important for patients and healthcare providers in Sri Lanka and similar emerging markets. Access to advanced robotic surgery can improve clinical outcomes and attract medical tourism, while also building local surgical expertise. However, the long-term impact will depend on factors such as cost, training, and ongoing support from SS Innovations.
As the company continues to pursue regulatory approvals and expand its global footprint, industry observers will be watching whether it can maintain its rapid procedure growth and translate installations into sustained financial performance. For now, the launch of Sri Lanka's first robotic cardiac surgery program represents a tangible step forward in the global adoption of robotic-assisted surgery.
NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
